On 21 May 2026, Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) repurchased 23,100 H-shares on the Hong Kong Stock Exchange at prices between HKD 28.20 and HKD 30.48, for a total consideration of HKD 0.67 million. The volume-weighted average purchase price was HKD 29.21 per share. All repurchased shares are being held as treasury stock.

Following the transaction, the company’s outstanding share count declined by 0.02 % to 135.46 million shares, while treasury stock increased to 758,100 shares. Total issued shares remained unchanged at 136.22 million.

The buyback forms part of the mandate approved on 12 February 2026, authorising repurchases of up to 13.62 million shares. To date, HANXBIO-B has repurchased 758,100 shares under this mandate, equivalent to 0.56 % of the share capital outstanding on the mandate date.

Under Hong Kong listing rules, HANXBIO-B is subject to a moratorium on issuing new shares or disposing of treasury shares until 20 June 2026.